Univ of Texas-M.D. Anderson Cancer Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Manisha H
NCT03975231: Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Recruiting
1
6
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
City of Hope Medical Center, National Cancer Institute (NCI)
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
10/25
10/25
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
Busaudy, Naifa
NCT03975231: Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Recruiting
1
6
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
City of Hope Medical Center, National Cancer Institute (NCI)
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
10/25
10/25

Download Options